Core Insights - Aadi Bioscience has appointed David Dornan, PhD, as Chief Scientific Officer, bringing over 20 years of oncology drug discovery and development experience, particularly in antibody-drug conjugates (ADCs) [1][2][3] - The company is implementing a new strategic plan that includes the sale of FYARRO® to Kaken Pharmaceuticals for 100 million private placement financing [2][3] - Aadi's pipeline targets specific cancer markers such as PTK7, MUC16, and SEZ6, aiming to innovate cancer treatment through a next-generation linker-payload platform [3] Company Developments - The strategic plan was first announced in December 2024 and includes a definitive proxy statement filed on January 31, 2025, for a Special Meeting of Stockholders scheduled for February 28, 2025 [2] - Dr. Dornan's previous roles include CSO at Elevation Oncology and Bolt Biotherapeutics, where he led ADC development and clinical trials [3] - Aadi aims to leverage its ADC expertise and innovative strategies to enhance patient outcomes in oncology [3] Industry Context - The ADC field is experiencing significant transformation, and Aadi is positioned to contribute with its advanced tumor-targeting strategies [3] - The company emphasizes a commitment to translating scientific innovation into impactful therapies for patients with difficult-to-treat cancers [4]
Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer